Last reviewed · How we verify

IVFarma LLC — Portfolio Competitive Intelligence Brief

IVFarma LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Follitropin alfa (Primapur) Follitropin alfa (Primapur) phase 3 Gonadotropin; recombinant FSH FSH receptor (FSHR) Reproductive/Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  2. Fertility Biotech AG · 1 shared drug class
  3. LG Chem · 1 shared drug class
  4. Merck KGaA, Darmstadt, Germany · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IVFarma LLC:

Cite this brief

Drug Landscape (2026). IVFarma LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ivfarma-llc. Accessed 2026-05-14.

Related